Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1995 1
1999 1
2000 1
2001 3
2002 4
2003 3
2005 2
2006 3
2007 3
2008 4
2009 2
2010 3
2011 2
2013 2
2014 2
2015 1
2016 2
2017 2
2019 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Results by year
Filters applied: . Clear all
Page 1
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Solé M, Domingo-Domenech J, Villanueva A, Llovet JM. Tovar V, et al. Gut. 2017 Mar;66(3):530-540. doi: 10.1136/gutjnl-2015-309501. Epub 2015 Dec 11. Gut. 2017. PMID: 26658144 Free PMC article.
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Sia D, et al. Among authors: tovar v. Gastroenterology. 2013 Apr;144(4):829-40. doi: 10.1053/j.gastro.2013.01.001. Epub 2013 Jan 4. Gastroenterology. 2013. PMID: 23295441 Free PMC article.
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A. Bollard J, et al. Among authors: tovar v. Gut. 2017 Jul;66(7):1286-1296. doi: 10.1136/gutjnl-2016-312268. Epub 2016 Nov 14. Gut. 2017. PMID: 27849562 Free PMC article.
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, Higuera M, Pfister D, Ramadori P, Pinyol R, Solé M, Heikenwälder M, Friedman SL, Sia D, Llovet JM. Moeini A, et al. Among authors: tovar v. Gastroenterology. 2019 Nov;157(5):1383-1397.e11. doi: 10.1053/j.gastro.2019.07.028. Epub 2019 Jul 22. Gastroenterology. 2019. PMID: 31344396 Free PMC article.
Cancer gene discovery in hepatocellular carcinoma.
Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Zender L, et al. Among authors: tovar v. J Hepatol. 2010 Jun;52(6):921-9. doi: 10.1016/j.jhep.2009.12.034. Epub 2010 Mar 20. J Hepatol. 2010. PMID: 20385424 Free PMC article. Review.
Pathogenesis of hepatocellular carcinoma and molecular therapies.
Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Mínguez B, et al. Among authors: tovar v. Curr Opin Gastroenterol. 2009 May;25(3):186-94. doi: 10.1097/MOG.0b013e32832962a1. Curr Opin Gastroenterol. 2009. PMID: 19387255 Review.
[Cell biology and genetics in liver cancer].
Tovar V, Villanueva A, Llovet JM. Tovar V, et al. Gastroenterol Hepatol. 2007 Jun-Jul;30(6):360-9. doi: 10.1157/13107573. Gastroenterol Hepatol. 2007. PMID: 17662221 Review. Spanish.
41 results